{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-032535","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.309268+00:00","generated_at":"2026-06-04T15:00:24.079075+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Atossa regains Nasdaq minimum bid price compliance; stock remains listed","bullets":["Received Nasdaq letter on March 15, 2024 confirming regained compliance with Listing Rule 5550(a)(2).","Previously notified of deficiency on Sep 26, 2023 for failing to maintain $1.00 minimum closing bid for 30 consecutive days.","Regained compliance by achieving $1.00 closing bid for 10 consecutive trading days ending March 14, 2024.","No further delisting risk; common stock continues trading on Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-032535","json":"https://secwatch.observer/filing/0000950170-24-032535.json","markdown":"https://secwatch.observer/filing/0000950170-24-032535.md","text":"https://secwatch.observer/filing/0000950170-24-032535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024032535/0000950170-24-032535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024032535/atos-20240315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T15:00:24.079075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac2c30b3c176f82cbe57d65f108c970250a87fff","claim":"ATOSSA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"March 15, 2024, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously disclosed, on September 26, 2023, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company was","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024032535/0000950170-24-032535-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"compliance regained"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}